Compare Estee Lauder Companies Inc (EL) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs 22nd Century Group Inc — how do they compare? Estee Lauder Companies Inc trades at $98.16 (market cap $34.17B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Estee Lauder Companies Inc is far larger — about 54964.9× 22nd Century Group Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and 22nd Century Group Inc for 32 Days on average.
| EL | XXII | |
|---|---|---|
Market Cap | $34.17B | $621.67K |
Volume | 3,921,497 | 45,625 |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $119.61 | $483.00 |
52-Week Low | $67.23 | $0.80 |
Typical Hold Time | 122 Days | 32 Days |
Enterprise Value | $39.92B | -$3.69M |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $97.81, up 3.56% with recent earnings beats but faces fundamental challenges including a net loss of $1.13B in 2025. The stock shows neutral technical signals with support at $90 and resistance at $98, while analyst consensus remains positive with a $103 price target. Recent developments include AI partnerships and leadership changes aimed at revitalizing the brand.
The outlook hinges on margin recovery and revenue stabilization, with 2026 projections showing a return to profitability. Key risks include competitive pressures and execution of turnaround strategy, but institutional sentiment remains cautiously optimistic given the company's strong brand portfolio and digital initiatives.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
